Literature DB >> 14984856

Nicardipine versus nitroprusside for deliberate hypotension during idiopathic scoliosis repair.

Stewart J Lustik1, Peter J Papadakos, Kenneth V Jackman, Paul T Rubery, Karen L Kaplan, Ashwani K Chhibber.   

Abstract

STUDY
OBJECTIVE: To compare coagulation, blood loss, and transfusion requirements between patients receiving nicardipine and nitroprusside for deliberate hypotension during idiopathic scoliosis repair.
DESIGN: Prospective, randomized study.
SETTING: University hospital. PATIENTS: 51 ASA physical status I patients presenting for spine fusion for idiopathic adolescent scoliosis.
INTERVENTIONS: Patients were randomized to two groups to receive nicardipine or nitroprusside to maintain mean arterial pressure (MAP) between 55 and 65 mmHg. MEASUREMENTS: Blood loss, blood transfusions, and coagulation studies (thromboelastogram and platelet aggregation) before starting vasodilator, 30 minutes and 90 minutes after starting vasodilator, and 30 minutes after stopping vasodilator, were all recorded. MAIN
RESULTS: There was no difference between the groups in blood loss [nicardipine = 1,129 cc (893 to 1,480), nitroprusside = 960 cc (704 to 1,473)] and only one patient required a nonautologous transfusion. There were no differences in prothrombin time (pT, partial thromboplastin time (pTT), platelet count, or platelet aggregation between groups. There were more episodes of severe hypotension (MAP <45 mmHg) in the nitroprusside group (0% vs. 28%, p = 0.0175). On average, patients in the nicardipine group spent 21 minutes less in the recovery room than did the nitroprusside group (p = 0.043).
CONCLUSIONS: Nitroprusside's effect on platelet aggregation produces no increase in blood loss compared with nicardipine. Nicardipine causes less transient severe hypotension than nitroprusside, although both drugs are acceptable choices for obtaining the goals of deliberate hypotension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984856     DOI: 10.1016/j.jclinane.2003.05.002

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  7 in total

Review 1.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Effects of vasodilator and esmolol-induced hemodynamic stability on early post-operative cognitive dysfunction in elderly patients: a randomized trial.

Authors:  Sheng-Hui Sun; Lin Yang; De-Feng Sun; Yue Wu; Jun Han; Ruo-Chuan Liu; Li-Jie Wang
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

3.  A prospective, open-label trial of clevidipine for controlled hypotension during posterior spinal fusion.

Authors:  Hiromi Kako; Andrew Gable; David Martin; Allan Beebe; Arlyne Thung; Walter Samora; Jan Klamar; Tarun Bhalla; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jan-Feb

4.  Application of Controlled Hypotension During Surgery for Spinal Metastasis.

Authors:  Rong-Xing Ma; Rui-Qi Qiao; Ming-You Xu; Rui-Feng Li; Yong-Cheng Hu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Predictors of arterial blood pressure control during deliberate hypotension with sodium nitroprusside in children.

Authors:  David R Spielberg; Jeffrey S Barrett; Gregory B Hammer; David R Drover; Tammy Reece; Carol A Cohane; Scott R Schulman
Journal:  Anesth Analg       Date:  2014-10       Impact factor: 5.108

6.  Hemodynamic protective effects of epinephrine containing saline irrigation in biportal endoscopic lumbar surgery.

Authors:  Woo-Hyeong Ko; Yong-Hyun Cho; Won Jang; Sun-Hee Kim; Hyun-Seok Lee; Hyun-Cheol Ko; Jae-Hyun Kwon
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

7.  Sodium nitroprusside is not associated with metabolic acidosis during intraoperative infusion in children.

Authors:  Gregory B Hammer; Sara G Connolly; Scott R Schulman; Andrew Lewandowski; Carol Cohane; Tammy L Reece; Ravinder Anand; Jeff Mitchell; David R Drover
Journal:  BMC Anesthesiol       Date:  2013-04-30       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.